Benzinga | Aug 26, 2020 07:07AM EDT

Clearside Biomedical Announces Three Additional Patents In US And Europe

- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE -

ALPHARETTA, Ga., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the recent issuance of three additional patents in the United States and Europe.

The United States Patent and Trademark Office (USPTO) recently granted patent number 10,722,396 to Clearside. This patent covers Clearside's SCS Microinjector(r) for the suprachoroidal administration of axitinib (CLS-AX) and expires in 2034.

The European Patent Office (EPO) issued two patents in the largest European markets. Patent number 2,563,429 expires in 2031 and covers a device for the suprachoroidal administration of any therapeutic agent. Patent number 2,916,827 expires in 2033 and covers the use of XIPERE(tm) (triamcinolone acetonide suprachoroidal injectable suspension) and the treatment of uveitis and other posterior ocular diseases with triamcinolone acetonide.

Clearside's 21 granted U.S. patents and its 20 granted European patents provide extensive coverage of the SCS Microinjector device, the use of the device, administration of any drug into the suprachoroidal space by injection, as well as specific product candidates.

"Clearside is the market leader in suprachoroidal delivery, and the issuance of these patents in two of the largest world markets significantly strengthens the IP portfolio governing our proprietary SCS Microinjector and our product candidates," said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. "We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. We look forward to achieving additional milestones by the end of 2020 as we and our partners expect to have three product candidates delivered via our SCS Microinjector in four clinical trials."